Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
BridgeBio Pharma (Nasdaq: BBIO) has announced the formation of a new joint venture, GondolaBio, in collaboration with a syndicate of prominent investors. 22 August 2024
Texas, USA-based Coya Therapeutics announced that Arun Swaminathan has been promoted to the role of chief executive (CEO) effective November 1, 2024. 22 August 2024
Shares of US clinical-stage biotech Kymera Therapeutics, Inc. declined 5% to $42.05 after it announced a public offering of $200 million in common stock and pre-funded warrants. 21 August 2024
The US Food and Drug Administration (FDA) has granted tentative approval of Liquidia Corp’s Yutrepia (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). 21 August 2024
Swiss mitochondrial therapeutics developer Vandria today announced the second closing of its Series A financing, bringing the final amount raised to date to $30.7 million (28.3 million francs). 21 August 2024
Pathalys Pharma, a private biopharmaceutical company based in North Carolina, USA, has announced the successful closure of a $105 million series B financing round. 21 August 2024
California, USA-based clinical-stage biopharmaceutical company 89bio has appointed Francis Sarena as chief operating officer (COO), effective August 5, 2024. 20 August 2024
MindBio Therapeutics yesterday reported durability data from Phase IIa clinical trials in depressed patients testing MB22001, MindBio's proprietary self-administered take home microdose of lysergic acid diethylamide (LSD). 20 August 2024
Avidity Biosciences (Nasdaq: RNA) has successfully closed its previously announced public offering, raising approximately $345.1 million. 19 August 2024
USA-based biotech Tiziana Life Sciences today announced the appointment of Ivor Elrifi as its chief executive (CEO), effective immediately. 19 August 2024
Texan firm Moleculin Biotech (Nasdaq: MBRX) has announced a public offering, raising approximately $5.5 million with stock priced at $2.23 per share. 16 August 2024
US pharma giant Pfizer and German partner BioNTech today announced mixed top-line results from their Phase III clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. 16 August 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
Shanghai-based OcuMension Therapeutics (HKSE: 1477) has reached an agreement with Alcon (NYSE: ALC) to acquire commercialization rights in China for several of its dry eye products. 15 August 2024